Ocumension Therapeutics

1477

KYG674111011

Ocumension Therapeutics is a China-based holding company principally involved in the discovering, developing and commercializing ophthalmic therapies. Its main products include OT-401 (YUTIQ), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-301 (NCX 470), OT-101 and OT-202, among others. The Company conducts its businesses in the domestic market.

Sector

Pharmaceuticals

Calendar

2024-08-22 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Ocumension Therapeutics

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

5.49 CNY

Average target price

7.77 CNY

Spread / Average Target

+41.53%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
OCUMENSION THERAPEUTICS	-11.08%	542M
ELI LILLY AND COMPANY	+24.60%	672B
NOVO NORDISK A/S	+24.08%	550B
JOHNSON & JOHNSON	-5.63%	351B
MERCK & CO., INC.	+15.37%	317B
ABBVIE INC.	+7.38%	292B
ASTRAZENECA PLC	+3.26%	211B
NOVARTIS AG	+0.78%	203B
PFIZER, INC.	-9.69%	144B
AMGEN INC.	-6.63%	141B

Other Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:35 2024-04-19 am EDT			5-day change	1st Jan Change
5.94 ^HKD	-2.94%		+0.85%	-11.08%

Apr. 15	Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug	MT
Apr. 15	Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China	CI

Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug	Apr. 15	MT
Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China	Apr. 15	CI
Ocumension Therapeutics' Eye Drug Completes Clinical Trials, to Apply for NDA Soon	Apr. 08	MT
Ocumension Therapeutics Announces Completion of the Phase III Clinical Trial of OT-702 in China	Apr. 08	CI
Ocumension Therapeutics’ Loss for 2023 Narrows; Shares Down 4%	Mar. 22	MT
Ocumension Therapeutics Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Ocumension Therapeutics' Phase 2 Trial for Dry Eye Treatment Meets Clinical Endpoints	Mar. 14	MT
Ocumension Therapeutics Announces Phase II Clinical Trial of OT-202	Mar. 14	CI
Ocumension Therapeutics Cuts Shareholding in Nasdaq-Listed EyePoint Pharmaceuticals	Jan. 17	MT
Ocumension Therapeutics Gets Nod to Register Iluvien in Hong Kong	Dec. 20	MT
Ocumension Therapeutics Receives Approval for Marketing OT-703 in Hong Kong	Dec. 20	CI
Ocumension Therapeutics commences an Equity Buyback for 69,071,128 shares, representing 10% of its issued share capital, under the authorization approved on June 16, 2023.	Dec. 13	CI
Ocumension Says Core Product Added to China's National Reimbursement Drug List	Dec. 13	MT
China Includes Ocumension's Middle Eye Infection Treatment in Drug Reimbursement List	Dec. 13	MT
Eyepoint Pharmaceuticals Insider Sold Shares Worth $19,510,637, According to a Recent SEC Filing	Dec. 08	MT
Ocumension Therapeutics Completes Patient Enrollment for Post-Operative Inflammation Drug in China	Nov. 29	MT
Ocumension Therapeutics Completes Enrollment in the Phase Iii Clinical Trial of OT-502 in China	Nov. 29	CI
Ocumension Therapeutics Plans HK$100 Million Share Buyback	Nov. 28	MT
Ocumension Enrolls 213 Patients for Phase II Trial of Eye Medication in China	Nov. 22	MT
Ocumension Therapeutics Completes Patient Enrollment in the Phase II Clinical Trial of OT-202 in China	Nov. 21	CI
Ocumension Therapeutics Announces the Change of Principal Place of Business, Effective September 30, 2023	23-09-29	CI
Ocumension Therapeutics Announces Executive Changes, Effective September 30, 2023	23-09-29	CI
Ocumension Therapeutics Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24	CI
Ocumension Therapeutics Enrolls 263 Patients in China Study of Postoperative Inflammation Drug	23-08-14	MT
Ocumension Therapeutics Announces patient Enrollment Completed in the Real-World Study of OT-502 in Hainan Boao	23-08-14	CI